Celldex Therapeutics (CLDX) grants 20,000 stock options to senior VP

Rhea-AI Filing Summary

Celldex Therapeutics, Inc. granted Senior Vice President and Chief Business Officer Ronald Pepin an incentive stock option covering 20,000 shares of common stock. The option has an exercise price of $34.09 per share and was issued under the company’s 2021 Omnibus Equity Incentive Plan.

According to the vesting schedule, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The option expires on June 25, 2036, and Pepin holds 20,000 derivative securities following this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider PEPIN RONALD

Role SR. VP & CBO

Type	Security	Shares	Price	Value
Grant/Award	Incentive Stock Option (right to buy)	20,000	$0.00	--

Holdings After Transaction: Incentive Stock Option (right to buy) — 20,000 shares (Direct, null)

Footnotes (1)

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

Key Figures

Option grant size: 20,000 options Exercise price: $34.09 per share Post-grant derivative holdings: 20,000 derivative securities +3 more

6 metrics

Option grant size 20,000 options Incentive Stock Option grant to Ronald Pepin

Exercise price $34.09 per share Strike price of Incentive Stock Option

Post-grant derivative holdings 20,000 derivative securities Total options held following transaction

Initial vesting date June 25, 2027 25% of option vests on this date

Full vesting schedule Remaining 75% over 12 quarters Equal quarterly vesting after June 25, 2027

Option expiration June 25, 2036 Expiration date of the option grant

Key Terms

Incentive Stock Option, 2021 Omnibus Equity Incentive Plan, vest, underlying security

4 terms

Incentive Stock Option financial

"Incentive Stock Option (right to buy) reported as the security title"

An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.

2021 Omnibus Equity Incentive Plan financial

"Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan."

vest financial

"25% vest on June 25, 2027 and the remainder vest quarterly over 12 quarters."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

underlying security financial

"underlying_security_title is Common Stock for the option award"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:16 PM Accepted by SEC EDGAR 06/29/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PEPIN RONALD

(Last) (First) (Middle)

C/O CELLDEX THERAPEUTICS, INC.

53 FRONTAGE ROAD, SUITE 220

(Street)

HAMPTON NEW JERSEY 08827

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Celldex Therapeutics, Inc. [ CLDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SR. VP & CBO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (right to buy)(1)	$34.09	06/25/2026(1)		A		20,000		06/25/2027(2)	06/25/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

	/s/ Sam Martin, attorney-in-fact for Ronald A. Pepin, Ph.D.	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Celldex Therapeutics (CLDX) report in Ronald Pepin’s latest Form 4?

Celldex reported that Senior Vice President and Chief Business Officer Ronald Pepin received an incentive stock option for 20,000 shares. The grant is a compensation award under the 2021 Omnibus Equity Incentive Plan with a fixed exercise price and long-dated expiration.

How many Celldex (CLDX) stock options were granted to Ronald Pepin?

Ronald Pepin was granted incentive stock options covering 20,000 shares of Celldex common stock. This entire amount represents a new award, and following the grant he holds 20,000 derivative securities according to the reported post-transaction holdings.

What is the exercise price of Ronald Pepin’s Celldex (CLDX) stock options?

The incentive stock options granted to Ronald Pepin have an exercise price of $34.09 per share. This strike price is fixed in the award and applies to purchasing Celldex common stock upon future vesting and exercise of the options.

When do Ronald Pepin’s Celldex (CLDX) options vest and expire?

Twenty-five percent of the options vest on June 25, 2027, and the remaining 75% vest in equal quarterly installments over the subsequent 12 quarters. The option award expires on June 25, 2036, providing a long-term exercise window.

Under which plan were Ronald Pepin’s Celldex (CLDX) options granted?

The options were granted under Celldex’s 2021 Omnibus Equity Incentive Plan. This plan authorizes the company to issue equity-based compensation, such as incentive stock options, to executives and other participants as part of their long-term incentive packages.

Is Ronald Pepin’s Celldex (CLDX) Form 4 transaction an open-market stock purchase?

No, the filing shows a grant of incentive stock options as compensation, coded as a grant, award, or other acquisition. It is not an open-market purchase or sale of existing Celldex common shares, but a derivative award exercisable in the future.